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Psoriatic patients undergoing psoralen plus ultraviolet radiation (PUVA) therapy are susceptible for squamous cell
carcinoma and melanoma of the skin. To investigate the etiological relevance of PUVA for these diseases, we
performed mutation spectrometry on the cII transgene in mouse embryonic ﬁbroblasts treated with a single or split
PUVA dose (PUVA-I or PUVA-II, respectively). Both treatments were significantly mutagenic as they increased the
cII mutant frequency up to 3.7-fold over background, and produced different mutational spectra from that derived
spontaneously (po0.01), but not from one another. The signature of induced mutations, i.e., T to C transitions and
T to A transversions with significant site-speciﬁcities, i.e., adjacent to T bases at the 30-neighboring side and to
pyrimidines at the 50-neighboring side, was more pronounced after PUVA-II treatment. Also, the overall mutations
occurring at T bases with the same site-speciﬁcities were more prevalent after PUVA-II treatment. The characteristic
PUVA-induced mutations predominate in the p53 mutational spectrum in controlled in vivo test systems or in high-
dose PUVA-treated patients, and also are easily recognizable in the overall PUVA-treated patients. We conclude
that PUVA-induced mutagenesis is initiated by PUVA-I treatment and subsequently, augmented by PUVA-II treat-
ment, leaving a unique mutational signature on the cII transgene. The signature mutations of PUVA are discernible
in the p53 mutational spectrum in PUVA-treated patients but complex exposure to other therapeutic/environmental
carcinogens also leads to the frequent occurrence of other types of mutations in this population.
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Psoralens constitute a family of three-ringed heterocyclic
furocoumarins (Cimino et al, 1985), which are widely used in
the photochemotherapy of a variety of skin diseases in-
cluding psoriasis, vitiligo, and cutaneous T cell lymphoma
(Wang et al, 2001). The therapeutic effects of the photoac-
tivated psoralens are ascribed to their anti-proliferative
properties resulting from the interaction of these com-
pounds with cellular DNA. Upon irradiation with long-wave
ultraviolet light (UVA: 320–400 nm), the non-covalently in-
tercalated psoralens form covalently bound complexes,
monoadducts (MA), at the 3, 4 pyrone- or 40, 50 furan-sides
with the 5, 6 double bond of pyrimidines (principally thy-
mines). Being further UVA irradiated, the furan-side MA can
react with thymines on the complementary strand of the
DNA helix, forming interstrand cross-linked (ICL) psoralen-
adducts (Hearst et al, 1984). Both the monoaddition and
cross-linking of psoralens are highly sequence-specific as
they occur preferentially at the 50-ATA and 50-TA sequences
(Esposito et al, 1988). Also, both the MA and ICL psoralen-
adducts have varying biological properties in different test
systems. For example, the cytotoxicity and mutagenicity of
both the MA and ICL psoralen-adducts are distinct in yeast,
bacteria, rodent, and human cells (Piette et al, 1985; Islas
et al, 1991; Yandell et al, 1994; Cohen et al, 2002).
Experimentally, the lethal and/or mutagenic effects of
psoralen–DNA adducts are largely determined by the irra-
diation protocol. A single psoralen plus UVA treatment
(PUVA-I) yields a combination of MA and ICL psoralen-ad-
ducts. The PUVA-I followed by a second UVA irradiation
(PUVA-II), however, generates more homogeneous photo-
lesions by converting most, if not all, of the MA to ICL
psoralen-adducts (Yang et al, 1994). The PUVA-II treatment
has been shown to have equal cytotoxicity and mutageni-
city at the hypoxanthine–guanine phosphoribosyl transf-
erase locus in both human lymphoblasts and fibroblasts
relative to PUVA-I treatment (Chiou and Yang, 1995; La-
querbe et al, 1995). In contrast, the PUVA-II treatment has
exhibited greater mutagenicity in an exogenous supF gene
propagated in primate cells relative to PUVA-I treatment
(Bredberg and Nachmansson, 1987). In the same study, the
PUVA-I treatment showed almost no lethality, whereas the
PUVA-II treatment was highly cytotoxic; the extent of cyto-
toxicity of PUVA-II being directly related to the radiation
dose, i.e., the higher the UVA dose the lower the cell survival
(Bredberg and Nachmansson, 1987). Altogether, the lethal-
ity and mutagenicity of PUVA-I versus PUVA-II treatments
Abbreviations: DMEM, Dulbecco’s Modified Eagle’s Medium; E.
coli, Escherichia coli; ICL, interstrand cross-linked; MA, monoad-
ducts; 8-MOP, 8-methoxypsoralen; NER, nucleotide excision re-
pair; PBS, phosphate buffered saline; PUVA, psoralen plus ultra-
violet A radiation; SE, standard error; UV, ultraviolet
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appear to be species- and cell type-dependent, and af-
fected by the experimental conditions.
Accumulating epidemiologic data show the susceptibility
of PUVA-treated patients for a subsequent melanoma- or
squamous cell carcinoma of the skin (Stern et al, 1997). To
unravel the potential involvement of the PUVA-induced
photolesions in these cancers, it is important to mechanis-
tically explore the biological fates of MA and ICL psoralen-
adducts in vivo. In this study, we investigated the biological
consequences of PUVA-I and PUVA-II treatments in Big
Blue mouse embryonic fibroblasts. This transgenic model
system is amenable to a variety of experimental conditions,
e.g., irradiation protocol (Jakubczak et al, 1996). It also has
the advantage of not being biased for strand specific mu-
tagenesis because the cII mutational target gene is a
chromosomally integrated non-transcribed transgene
(Swiger et al, 1999). The easily recoverable cII transgene
is relatively short in length (294 base pairs), thereby provid-
ing the opportunity for multiple DNA sequence analyses
from minute amounts of DNA. Here, we performed the
PUVA-I and PUVA-II treatments on Big Blue mouse embry-
onic fibroblasts, and investigated the consequent cytotox-
icity and mutagenicity utilizing a lambda phage-based
mutation detection system. Subsequently, we made a com-
parative analysis between our cII mutation spectrometry
data and the existing data on p53 mutations in the PUVA-
treated patients compiled from studies entered into the
IARC Database of TP53 Somatic Mutations (www-p53.
iarc.fr/p53DataBase.htm; R8 version) or otherwise listed in
PubMed (Seidl et al, 2001; Stern et al, 2002).
Results
Cytotoxicity examination Both PUVA-I and PUVA-II treat-
ment were cytotoxic in mouse embryonic fibroblasts (Fig 1).
The severity of cytotoxicity was, however, significantly high-
er in PUVA-II treatment than in PUVA-I treatment (po0.03).
Whereas the UVA irradiation alone was considerably and
dose-dependently cytotoxic, the 8-methoxypsoralen (8-
MOP) alone treatment did not show any cytotoxic effects
(Fig 1). Twenty-four hours after treatments, we performed an
additional cytotoxicity examination, which showed a slightly
but non-significantly lower viability for most treated cells
(data not shown).
cII Mutant frequency and mutational spectrum analy-
ses Both PUVA-I and PUVA-II treatment were mutagenic in
mouse embryonic fibroblasts as they significantly increased
the cII mutant frequency (up to 3.7-fold relative to back-
ground; po0.01). The induced cII mutant frequencies by
PUVA-I and PUVA-II treatments were not, however, sig-
nificantly different from one another (Fig 2). The 8-MOP
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Figure 1
Cytotoxic effects of psoralen
plus ultraviolet A radiation
(PUVA)-I and PUVA-II treat-
ments on Big Blue mouse
embryonic fibroblasts. Conflu-
ent cell cultures were treated with
8-methoxypsolaren (8-MOP) (10
mM, 30 min) and UVA radiation
(1.05 and/or 2.1 J per cm2) indi-
vidually and combined, and cell
viability was determined by the
trypan blue exclusion assay. Via-
bility is expressed as a percent-
age of total cell number. Results
are expressed as medians of two
independent experiments, with
each experiment run in triplicate
(medians of triplicate measure-
ments were used for final aver-
aging). Error bars¼SE.
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Figure2
Mutant frequency of the cII transgene in Big Blue mouse embry-
onic fibroblasts treated with 8-methoxypsolaren (8-MOP) (10 lM,
30 min) and ultraviolet A (UVA) radiation (1.05 and/or 2.1 J per cm2)
individually and combined. Quantification was done 8 d after treat-
ments using the lambda select-cII mutation detection system for Big
Blue rodents (Stratagene), a phage-based assay that permits detection
of mutations within the transgene on the basis of plaque formation.
Mutant frequency was determined from a minimum of 3  105 plaques.
Results are expressed as medians of two independent experiments,
with each experiment run in triplicate (medians of triplicate measure-
ments were used for final averaging). Error bars¼SE.
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treatment alone did not affect the cII mutant frequency rel-
ative to background. The UVA irradiation alone at the higher
dose, however, increased the cII mutant frequency 1.9-fold
over background (Fig 2).
For mutational spectra analyses, DNA sequencing was
performed on the verified cII plaques from samples treated
with PUVA-I or PUVA-II, or irradiated with UVA alone, or
from the control-treated samples (number of sequenced
plaques¼116, 146, 120, 173, respectively). Overall, DNA
sequencing confirmed a mutated cII in 495% of all analy-
zed plaques. Of these, the vast majority were single-base
substitutions and less frequently insertions, deletions, and
multiple base substitutions/deletions/insertions, respective-
ly (Fig 3a–d). In both induced and spontaneous mutational
spectra, there were four ‘‘jackpot’’ mutations at nucleotide
positions 179–184 [G insertion/deletion], 196 [G ! A tran-
sition], 211 [G ! C transversion] and 221 [T ! G transver-
sion] (Fig 3a–d). These jackpot mutations are common
phenomena in transgenic model systems, and have been
consistently reported by us (Besaratinia and Pfeifer, 2003)
as well as by others (Harbach et al, 1999). Presumably,
these jackpot mutations occur in the early development of
the transgenic rodents and undergo clonal expansion such
that many cells from various tissues harbor the same type of
mutations. Alternatively, they might represent actual hot-
spots of spontaneous mutagenesis (Swiger et al, 1999).
Regardless of their origin, it is methodologically appropriate
to exclude all jackpot mutations from the comparative
spectra analyses. Excluding the jackpot mutations, the
spectra of mutations induced by PUVA-I or PUVA-II treat-
ment were significantly different from that derived sponta-
neously, or produced by UVA irradiation alone (po0.01).
The mutational spectra induced by PUVA-I and PUVA-II
treatment did not, however, differ significantly from one
another (p¼0.18). The mutational spectrum produced
by UVA irradiation alone was not significantly different
from the spontaneously derived mutational spectrum, either
(p¼ 0.26).
As mentioned earlier, a DNA strand bias for cII muta-
genesis in the Big Blue system is principally ruled out
(Swiger et al, 1999). Therefore, we combined the strand
mirror counterparts of all transitions and transversions, and
compared the specific types of mutation between different
treatment groups. As shown in Fig 4a, T ! CþA ! G
transitions were the hallmark of mutations induced by both
PUVA-I and PUVA-II treatment, relative to control. The in-
creased frequency of T ! CþA ! G transitions initiated
by PUVA-I treatment was augmented after PUVA-II treat-
ment reaching a statistically significant level relative to con-
trol (po0.03). The majority of these transitions occurred at
sites adjacent to A/T bases at the 30-neighboring side (ap-
proximately 66% in both PUVA-I and PUVA-II, and 39% in
control; po0.01). Also, for the most part, these transitions
were preceded with a pyrimidine (T/C) as the 50-neighboring
base (77%, 81%, and 42% in PUVA-I, PUVA-II, and control,
respectively). Likewise, of all mutations occurring at T/A
sites induced by PUVA-I and PUVA-II treatments, approx-
imately 56% and 69%, respectively, had A/T bases at the
30-neighboring side, whereas the respective mutations in
control were less than 29%. In addition, the overall muta-
tions at T/A sites induced by PUVA-I and PUVA-II treat-
ments had predominantly an adjacent pyrimidine at the 50-
side (po0.01, relative to control).
Compared with UVA irradiation alone, both PUVA-I and
PUVA-II treatment increased the frequencies of
T ! AþA ! T transversions (p¼0.09 and 0.01, respec-
tively) and deletions/insertions (p¼0.05 and 0.17, respec-
tively). A frequent single deletion was observed at a stretch
of adenines preceded with a thymine (50-ATAAAAAA: nuc-
leotide positions: 239–246). This deletion event occurred 11
times after PUVA-I and PUVA-II treatments combined; how-
ever, it was totally absent in the mutational spectrum pro-
duced by UVA irradiation alone. Two occurrences of this
deletion were also observed in the spontaneously derived
mutational spectrum. The latter could relate to the prone-
ness of the adenine repeat to slippage during DNA replica-
tion. (Fig 3a–d).
For comparative analysis, we complied the known
p53 mutation data of the PUVA-treated patients (www-p53.
iarc.fr/p53DataBase.htm; R8 version) (Seidl et al, 2001;
Stern et al, 2002). As shown in Fig 4b, the established hall-
mark of mutations induced by PUVA in the cII transgene
was easily discernable in the p53 mutational spectrum of
the PUVA-treated patients.
Discussion
Molecular epidemiology has shown that the etiology of
specific cancers can be inferred from the mutation spect-
rometry of the relevant carcinogenic agents. Some car-
cinogens leave a unique mutational signature on the
cancer-related genes, e.g., oncogene or tumor suppressor
gene, in the genome. This is best represented by the ex-
emplary cases of human skin and lung cancers for which
solar UV radiation and tobacco-derived polycyclic aromatic
hydrocarbons, respectively, are identified as the likely caus-
ative agents (Pfeifer and Denissenko, 1998). The mutational
spectra experimentally induced by the respective agents,
i.e., C to Tor CC to TT transitions at dipyrimidine sites and G
to T transversions at methylated CpG dinucleotides, closely
resemble those established for p53 mutations in skin and
lung cancer patients, respectively (Pfeifer and Denissenko,
1998). In this study, we used mutation spectrometry to
investigate the etiological relevance of photo-activated
psoralens for squamous cell carcinoma and melanoma of
the skin commonly seen in patients who have undergone
PUVA therapy (Stern et al, 1997).
Cytological examination of the cells that had undergone
a single- or split-PUVA treatment (PUVA-I and PUVA-II, re-
spectively) showed that both treatments were cytotoxic, the
latter having significantly greater deteriorating effects (Fig
1). Both PUVA-I and PUVA-II treatment were significantly
mutagenic in Big Blue mouse embryonic fibroblasts, the
former inducing a slightly higher cII mutant frequency (Fig 2).
The lower frequency of mutations induced by PUVA-II is
concurrent with the higher cytotoxicity of this treatment.
Although the PUVA-I treated cells had a high population-
doubling rate and underwent one passaging during the 8-
day growing period, the PUVA-II-treated cells could barely
reach full confluency at the end of culturing. In agreement
with the induction of mutant frequency, the spectra of
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Figure 3
Detailed mutational spectra of the cII transgene in Big Blue mouse embryonic fibroblasts treated with psoralen plus ultraviolet A (PUVA)-I,
PUVA-II, and irradiated with UVA. (a) Control non-treated cells, (b) UVA-irradiated cells, (c) PUVA-I-treated cells, and (d) PUVA-II-treated cells (total
number of sequenced mutant plaques¼173, 120, 116, and 146, respectively). Substituted bases are in bold. Deleted bases are underlined; multiple
deletions are continuously underlined. Inserted bases are shown with an arrow. Mutation multiplicity is shown by the number above each base, e.g.,
G20¼ twenty occurrences of guanine deletion. Numbers below the bases are the nucleotide positions.
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mutations produced by PUVA-I and PUVA-II treatments
were significantly different from the spontaneously derived
and UVA-only derived mutational spectra. The overall spec-
tra of mutations induced by PUVA-I and PUVA-II treatments
were not significantly different from one another; however,
the signature of induced mutations was more pronounced
after PUVA-II treatment. Accordingly, T ! CþA ! G tran-
sitions and T ! AþA ! T transversions with significant
site-specificities, i.e., adjacent to A/T bases at the 30-neigh-
boring side and to pyrimidines (T/C) at the 50-neighboring
side, were more discernible after PUVA-II treatment than
after PUVA-I treatment. Also, the overall mutations occur-
ring at T/A bases with the above-mentioned site-specifi-
cities were more distinguishable in the PUVA-II mutational
spectrum than in the PUVA-I spectrum of mutations (Fig 3c,
d). These observations give rise to the idea that PUVA-I
treatment triggers mutagenesis via a specific pathway on
which PUVA-II treatment impinges more intensely.
It has previously been demonstrated that PUVA-I treat-
ment induces a combination of furan/pyrone-side MA and
ICL psoralen-adducts at different proportions depending on
the test system, whereas PUVA-II treatment converts the
majority of the cross-linkable furan-side MA thereby, giving
rise to predominantly ICL psoralen-adducts (Islas et al,
1991; Yang et al, 1994). Although MA may persist in rep-
licated DNA, ICL psoralen-adducts represent an absolute
block to the progression of the replication fork (Vos and
Hanawalt, 1987). The latter is reflected by the herein ob-
served severe cytotoxicity of ICL psoralen-adducts (Fig 1).
The ICL psoralen-adducts are also known to completely
block the transcription machinery (Kupiec, 2000). Whilst MA
are largely removed by nucleotide excision repair (NER) in
a relatively error free fashion (Vos and Hanawalt, 1987), the
ICL psoralen-adducts undergo mostly recombinational re-
pair, which might be a mutagenic pathway (Yandell et al,
1994; Grossmann et al, 2001). Transcription-coupled repair
and ‘‘post-replicative repair’’ are also implicated in the
processing of both MA and ICL psoralen-adducts. Mech-
anistically, these repair processes involve initial damage
recognition followed by excision of the lesion and transle-
sion synthesis with error-prone or error-free polymerases
across the gap. Although the complex pathway of recom-
binational repair for ICL psoralen-adducts is not fully delin-
eated, it is thought to include incision by endonucleases,
polymerization, homologous recombination, excision of the
cross-link, a second step of repair synthesis, and finally
ligation. Such sequential recombinogenic events have the
potential to induce mutations (Grossmann et al, 2001;
Cohen et al, 2002).
Previously, we have shown that early stage Big Blue
mouse embryonic fibroblasts possess a quantifiable NER to
repair a variety of bulky DNA adducts (You et al, 1999).
Scant data are available on the ability of mouse fibroblasts
to perform recombinational DNA repair. In the Big Blue cI/cII
mutation detection system, large deletions/insertions along
the cII locus that change the structure of the adjacent O
gene, which is essential for lytic growth, will not be pheno-
typically expressed. The occurrence of such events, how-
ever, can be noticed from a low packaging efficiency
because the affected LIZ construct loses its optimal size
and as a result, cannot be efficiently packaged into the vi-
able phages (Stratagene Instruction Manual). This scenario
is very improbable to have occurred in this study because
both PUVA-I- and PUVA-II-treated cells yielded comparably
high packaging efficiency. Notable is, however, the occur-
rence of few small tandem base deletions consequent to
both PUVA-I and PUVA-II treatment. A similar pattern of
small tandem base deletions was observed in transgenic
mouse embryonic fibroblasts irradiated with a mutagenic
dose of 18 J per cm2 of UVA, an agent known to cause DNA
strand breaks possibly through recombinational DNA repair
(Besaratinia et al, 2004). A single base deletion occurred
frequently at a homopolymeric run of adenines preceded
with a thymine (nucleotide position: 239–246) after both
PUVA-I and PUVA-II treatment (Fig 3). The relative frequen-
cy of this single deletion was, however, not different be-
tween PUVA-I- and PUVA-II-treated cells. This together with
the similar spectra of mutations induced by PUVA-I and
PUVA-II treatments implies that in our system, an individual
repair machinery handles both PUVA-I- and PUVA-II-in-
duced lesions. Such machinery of repair is likely to recruit
translesion synthesis using error-prone-polymerases to
bypass both MAs and ICL-psoralen-adducts.
To see the significance of our findings for cancer epide-
miology, we analyzed the existing data on p53 mutations in
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Figure 4
Mutation spectrometry data. (a) Mutational spectra of the cII trans-
gene in Big Blue mouse embryonic fibroblasts with psoralen plus ul-
traviolet A (PUVA)-I, PUVA-II, and irradiated with UVA. For comparison,
the strand mirror counterparts of all transitions and transversions were
combined for each treatment group. Ins, insertion; Del, deletion. As
compared with ‘‘non-treated control’’; po0.03. (b) p53 mutational
spectrum in PUVA-treated patients (n¼ 120; from tumor specimens).
Data are pooled from the studies entered into the IARC Database of
TP53 Somatic Mutations (R8 version; www-p53.iarc.fr/p53DataBase.
htm) or otherwise listed in PubMed (Seidl et al, 2001; Stern et al, 2002).
Del, deletion; C:C ! T:T, tandem transitions; mCpGs, methylated CpG
dinucleotides.
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PUVA-treated patients (www-p53.iarc.fr/p53DataBase.htm;
R8 version) (Seidl et al, 2001; Stern et al, 2002). As shown in
Fig 4b, the established signature of PUVA-mutagenesis is
easily distinguishable in the p53 mutational spectrum of the
PUVA-treated patients (n¼ 120; from tumor specimens).
Stratified for PUVA dose, the characteristic PUVA-induced
mutations predominate in patients with high exposure to
psoralen and/or UVA (Stern et al, 2002). In addition, UV-
associated transitions ‘‘C to T and CC to TT at dipyrimidine
sites’’ are readily noticeable in this population (Fig 4b). It
needs to be taken into account that PUVA-treated patients
are likely to have prior therapeutic/environmental exposure
to a wide range of physical/chemical carcinogens, e.g., UV
light, ionizing radiation, topical tar preparations, methotrex-
ate, cyclosporine, etc. It is also known that these patients
intentionally seek sunlight exposure because of its palliative
effects. As such, PUVA might act as a promoter and not as
an initiator in patients previously exposed to other carcin-
ogens. PUVA could also have co-carcinogenic effects in
patients with simultaneous exposure to other carcinogenic
agents (see Gasparro, 2000 for detailed information). Inter-
estingly, under well-controlled experimental conditions, the
mutational signature of PUVA was readily detectable in the
p53 gene in mouse skin tumors (Nataraj et al, 1996) and in
yeast harboring a human p53 cDNA (Monti et al, 2000), as
well as in the adenine phosphoribosyltransferase gene in
Chinese hamster ovary cells (Sage et al, 1993). Such ob-
servations in experimental systems versus humans are elab-
orated upon in our recent work where we demonstrated that
the mutational signature of mixed or combined carcinogens
might not always be straightforward due to the synergistic
and/or multiplicative effects of the carcinogenic agents (Be-
saratinia and Pfeifer, 2003). Lastly, it needs to be acknowl-
edged that genes other than p53 might be of influence in the
development of neoplasia associated with PUVA therapy.
In summary, we have demonstrated a unique mutageni-
city of PUVA treatment in the cII transgene in mouse em-
bryonic fibroblasts. The established signature of mutations
induced by PUVA is not, however, exclusively manifested in
the p53 mutational spectrum of all PUVA-treated patients
possibly due to the complexity of carcinogen exposure in
these individuals.
Materials and Methods
Cell culture and treatments Early passage Big Blue mouse em-
bryonic fibroblasts (prepared from 13.5-day-old embryos) were
grown to monolayer confluence (70%) in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine se-
rum. The cells were kept in phenol red and serum free medium,
Opti-MEM I (Invitrogen, Carlsbad, California), at least 12 h prior to
treatments. The cells were treated with 10 mM 8-MOP (Sigma-
Aldrich, Saint Louis, Missouri) or control solvent, dimethylsulfoxide,
for 30 min in the dark. Following multiple washes with phosphate-
buffered saline (PBS), the cells were irradiated (in Opti-MEM I) with
a single dose of 1.05 J per cm2 UVA (PUVA-I treatment), or a
double dose of 1.05þ 2.1 J per cm2 UVA (PUVA-II treatment) with
thorough PBS washes in between irradiations. The UVA source
consisted of two black-light lamps, F15T8.BLB, 15W (each), 365
nm (General Electric, Los Angeles, California), being filtered
through a 3 mm window glass, yielding an average fluence rate
of 1.75 mW per cm2 determined by a UVX radiometer (Ultraviolet
Products, Upland, California). For homogeneous irradiation of the
cells, the culture Petri dishes were placed on the filter glass and
were rotated every 2–3 min during the course of irradiation (10–30
min). Immediately after the PUVA-I and PUVA-II treatments, the
cells were harvested by trypsinization and evaluated for survival
using the trypan blue dye exclusion technique. Alternatively, the
cells were cultured in complete growth medium for an additional
8 d after which, they were analyzed for mutant frequency and mu-
tational spectrum of the cII transgene. The 8-d growing period is
essential for the fixation of all induced/spontaneously derived mu-
tations into the genome. Except for the PUVA-II-treated cell cul-
tures, all other cultures were passed once or twice during the 8-d
growing period. The latter cell cultures underwent three to five
population doublings. All experiments were run in triplicate.
Genomic DNA isolation Genomic DNA was isolated using a
standard phenol and chloroform extraction and ethanol precipita-
tion protocol (Besaratinia and Pfeifer, 2003). The DNA was dis-
solved in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) and kept
at 801C until further analysis.
cII Mutant frequency analysis The cII mutant frequency and mu-
tational spectrum were determined using the previously published
protocols (Besaratinia and Pfeifer, 2003) (available online as Sup-
plementary Material).
Statistical analysis Results are expressed as medians  SE. All
variables between two treatment groups were compared by the
Wilcoxon signed rank test. The entire mutational spectra and the
specific types of mutation in different treatment groups were com-
pared by the hypergeometric test of Adams and Skopek (Adams
and Skopek, 1987) and w2 test, respectively. Values of pp0.05
were considered statistically significant.
The experiments were approved by the institutional animal care
committee of the Beckman Research Institute of the City of Hope
(City of Hope, Duarte, CA). The institutional and national guide for
the care and use of laboratory animals was followed thoroughly.
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supported by a grant from the National Institute of Environmental
Health Sciences (ES06070) to G. P. P.
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